Cancer and immunosuppression: Pro- and antitumoral effects of immunosuppressive drugs;Cancers et immunosuppression: Effet pro- et antitumoral des traitements immunosuppresseurs

Nephrologie et Therapeutique

Volumn 1, Issue 1, 2005, Pages 23-30

  Thaunat, Olivier ^a   Morelon, Emmanuel ^b  

^a INSERM   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Calcineurin inhibitors; Cancer; Carcinogenesis; Immunosuppressive drugs; mTOR inhibitors; Organ transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; EVEROLIMUS; INTERLEUKIN 6; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CARCINOGENESIS; CELL PROLIFERATION; DNA REPAIR; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; METASTASIS; NONHUMAN; ORGAN TRANSPLANTATION; REVIEW; T LYMPHOCYTE; TUMOR CELL LINE; VIRUS REPLICATION;

EID: 23244444096     PISSN: 17697255     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nephro.2005.01.003     Document Type: Short Survey

References (45)

1. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-9.
2. Penn I. Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000;23:101-13.
3. Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000;7:147-56.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348(17):1681-91.
5. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996;61(5):715-21.
6. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Harden PN. Non-melanoma skin cancer risk in the Queensland renal transplant population. Br J Dermatol 2002;147(5):950-6.
7. Webb MC, Compton F, Andrews PA, Koffman CG. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 1997;29(1-2):828-30.
8. Cotran RS. Diseases of whites cells, lymph nodes and spleen. In: Cotran VK RS, Robbins SC, editors. Pathologic basis of disease. Philadelphia: Saunders WB; 1994. p. 629-47.
9. Wiesner RH. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group. Transplantation 1998;66(4):493-9.
10. Jonas S, Rayes N, Neumann U, Neuhaus R, Bechstein WO, Guckelberger O, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte giobulin. Cancer 1997;80(6):1141-50.
11. Bansal N, Houle A, Melnykowych G. Apoptosis: mode of cell death induced in T cell leukemia lines by dexamethasone and other agents. FASEB J 1991;5(2):211-6.
12. Rutz HP. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002;360(9349):1969-70.
13. Zhao JY, Ikeguchi M, Eckersberg T, Kuo MT. Modulation of multidrug resistance gene expression by dexamethasone in cultured hepatoma cells. Endocrinology 1993;133(2): 521-8.
14. Naumann U, Durka S, Weller M. Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? Oncogene 1998; 17(12):1567-75.
15. Nauck M, Roth M, Tamm M, Eickelberg O, Wieland H, Stulz P, et al. Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids. Am J Respir Cell Mol Biol 1997;16(4):398-406.
16. Chan GL, Erdmann GR, Gruber SA, Matas AJ, Canafax DM. Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients. J Clin Pharmacol 1990;30(4): 358-63.
17. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78(1A):44-9.
18. Taylor AE, Shuster S. Skin cancer after renal transplantation: the causal role of azathioprine. Acta Derm Venereol 1992;72(2):115-9.
19. Kuroki T, Matsushima T. Performance of short term tests for detection of human carcinogens. Mutagenesis 1987; 2(1):33-7.
20. Dalton A, Curtis D, Harrington CI. Synergistic effects of azathioprine and ultraviolet light detected by sister chromatid exchange analysis. Cancer Genet Cytogenet 1990; 45(1):93-9.
21. Lennard L, Thomas S, Harrington C, Maddocks J. Skin cancer in renal transplant recipients is associated with increased concentrations of 6-thioguanine nucleotide in red blood cells. Br J Dermatol 1985;113(6):723-9.
22. Kelly GE, Meikle W, Sheil AG. Scheduled and unscheduled DNA synthesis in epidermal cells of hairless mice treated with immunosuppressive drugs and UVB-UVA irradiation. Br J Dermatol 1987;117(4):429-40.
23. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Henderson RG, et al. Cyclosporin-A in clinical organ grafting. Transplant Proc 1981;13:349-58.
24. Tanner JE, Alfieri C. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease. Leuk Lymphoma 1996;21(5-6):379-90.
25. Ahlers C, Kreideweiss S, Nordheim A, Ruhlmann A. Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells. Eur J Biochem 1999;264(3): 952-9.
26. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397(6719): 530-4.
27. Mohri T, Kameshita I, Suzuki S, Hioki K, Tokunaga R, Takatani S. Rapid adhesion and spread of non-adherent colon cancer color201 cells induced by the protein kinase inhibitors, K252a and KT5720 and suppression of the adhesion by the immunosuppressants FK506 and cyclosporin A. Cell Struct Funct 1998;23(5):255-64.
28. Beatty PR, Krams SM, Esquivel CO, Martinez OM. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines. Transplantation 1998;65(9): 1248-55.
29. Pritchard DE, Singh J, Carlisle DL, Patierno SR. Cyclosporin A inhibits chromium(VI)-induced apoptosis and mitochondrial cytochrome c release and restores clonogenic survival in CHO cells. Carcinogenesis 2000;21(11):2027-33.
30. Hortelano S, Lopez-Collazo E, Bosca L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 1999; 126(5):1139-46.
31. Digits JA, Hedstrom L. Drug selectivity is determined by coupling across the NAD+ site of IMP deshydrogenase. Biochemistry 2000;39(7):1771-7.
32. Franchetti P, Grifantini M. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem 1999;6(7):599-614.
33. Boritzki TJ, Berry DA, Besserer JA, Cook PD, Fry DW, Leopold WR, et al. Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide). Biochem Pharmacol 1985; 34(7):1109-14.
34. Ahluwalia GS, Cooney DA, Marquez VE, Jayaram HN, Johns DG. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4- carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD). Biochem Pharmacol 1986;35(21):3783-90.
35. Tressler RJ, Garvin LJ, Slate DL. Anti-tumor activity of mycophenolate mofetil against human and mouse tumors in vivo. Int J Cancer 1994;57(4):568-73.
36. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22, 989) a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28(10):727-32.
37. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs 2002;3(8): 1249-53.
38. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21(1):99-102.
39. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19(56):6680-6.
40. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2):128-35.
41. Law BK, Chytil A, Dumont N, Hamiton EG, Waltner-Law ME, Aakre ME, et al. Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, onogene-transformed, and human cancer cells. Mol Cell Biol 2002;22(23):8184-98.
42. Luan FL, Hojo M, Mallucio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73(10):1565-72.
43. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55(9):1982-8.
44. Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000;97(8):4285-90.
45. Tanaka T, Takahara S, Hatori M, Suzuki K, Wang J, Ichimaru N, et al. A novel immunosuppressive drug, FTY220, prevents the cancer progression induced by cyclosporine. Cancer Lett 2002;181(2):165-71.